Elevated hepcidin levels are associated with poor survival outcomes in cancer patients, particularly during hematopoietic stem cell transplantation [9], and have been observed in various cancers, including colorectal carcinoma [10], breast carcinoma [11], esophageal carcinoma [12], urothelial and renal neoplasms [13] and hepatic carcinoma [14]. This evidence concerns the gene HAMP and hepatocellular carcinoma.